These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 33515938

  • 1. Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer.
    Sacdalan DB, Lucero JA.
    Cancer Treat Res Commun; 2021; 27():100319. PubMed ID: 33515938
    [Abstract] [Full Text] [Related]

  • 2. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS, Tung PH, Huang AC, Wang CC, Chang JW, Liu CY, Chung FT, Fang YF, Guo YK, Yang CT.
    BMC Cancer; 2021 Mar 24; 21(1):309. PubMed ID: 33761908
    [Abstract] [Full Text] [Related]

  • 3. Alectinib shows CNS efficacy in ALK-positive NSCLC.
    Gourd E.
    Lancet Oncol; 2018 Oct 24; 19(10):e520. PubMed ID: 30245054
    [No Abstract] [Full Text] [Related]

  • 4. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
    Morcos PN, Nueesch E, Jaminion F, Guerini E, Hsu JC, Bordogna W, Balas B, Mercier F.
    Cancer Chemother Pharmacol; 2018 Jul 24; 82(1):129-138. PubMed ID: 29748847
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Alectinib for advanced ALK-positive non-small-cell lung cancer.
    Ly AC, Olin JL, Smith MB.
    Am J Health Syst Pharm; 2018 Apr 15; 75(8):515-522. PubMed ID: 29467147
    [Abstract] [Full Text] [Related]

  • 7. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 15; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 8. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M, An Z, Tang Q, Ma Y, Yan J, Chen S, Wang Y.
    J Cell Mol Med; 2021 Oct 15; 25(19):9476-9481. PubMed ID: 34541785
    [Abstract] [Full Text] [Related]

  • 9. Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
    Masuda N, Ohe Y, Gemma A, Kusumoto M, Yamada I, Ishii T, Yamamoto N.
    Cancer Sci; 2019 Apr 15; 110(4):1401-1407. PubMed ID: 30776174
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators.
    N Engl J Med; 2017 Aug 31; 377(9):829-838. PubMed ID: 28586279
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.